Eli Lilly Gets Expanded Label Approval From FDA for Alopecia Drug
By Elias Schisgall
Eli Lilly received expanded label approval from the Food and Drug Administration for Olumiant, a drug for pediatric patients 12 years of age or older with severe alopecia areata.
The company said Friday that the FDA had approved the expanded U.S. label for the drug, known generically as baricitinib, based on the results of a Phase 3 study. Olumiant was previously approved for adults with moderately to severely active rheumatoid arthritis and severe alopecia areata.
"The visible and often extensive hair loss that comes with severe alopecia areata can have a profound impact on anyone, especially adolescents who are at a pivotal stage of life," Lilly Immunology president Adrienne Brown said. "Expanding Olumiant to patients as young as 12 provides them a much-needed treatment choice and reinforces our commitment to advancing care for people living with immune-mediated diseases."
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
September 25, 2026 17:41 ET (21:41 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States